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BACKGROUND

INTERVENTION

DISCUSSION

The opioid crisis in Washington State continues to
escalate with overdoses increasing each year. Innovative
solutions are needed to save lives.1

Patients identified by EMR keywords (opiate, opioid,
narcotic, heroin, IVDU, substance use, methamphetamine
use) were provided prescriptions for naloxone nasal spray at
time of discharge.
The outpatient pharmacy screened for recent prescriptions
to avoid duplication, and social work offered information
about financial assistance when needed. Upon discharge,
patients were advised to pick up the prescription from the
on-site Credena pharmacy.

Our intervention resulted in a statistically significant
increase in naloxone prescriptions. In February 2022, more
naloxone prescriptions were given than in any of the
preceding 13 months despite a 7.8 % decrease in the
number of patients with opioid disorder keywords in the
matched months in the preceding year. Additionally,
Credena pharmacy had an increase of three times the
prescriptions of naloxone during the start of this QI project.
While this pilot implementation proved successful,
barriers to long-term implementation still exist. These
include complex questions regarding sustainability for onsite pharmacies, difficulties communicating prescriptions to
patients, and uncertain patient compliance. Additional
tracking of filling of prescriptions, pharmacy logistics, use of
financial resources, and changes in mortality would be
needed to inform widespread policy changes.
Single dose, non-reusable nasal spray was prescribed;
however, the proliferation of fentanyl has complicated
naloxone intervention by often requiring multiple sequential
doses. Recent FDA approval of a higher 8mg dose may
further mitigation potential and warrants additional research.

METRICS

Naloxone is an opioid antagonist carried by emergency
personnel for overdose intervention. When offered via
take-home programs, naloxone decreases mortality.2

Naloxone prescriptions were written upon hospital
discharge, excluding EDs and inpatient psychiatric facilities,
from November 2021 to March 2022. Monthly prescription
totals and the number of patients with keywords were
compared with totals in the preceding year.

RESULTS

AIMS
Increase naloxone available to patients diagnosed with an
Opiate Use Disorder by providing a prescription for
naloxone/Narcan at time of discharge.
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PHARMACOLOGY
Naloxone is a
synthetic
morphinane
alkaloid with a high
affinity for the muopioid receptor and
is available by
intravenous,
intramuscular,
intraosseous,
subcutaneous,
sublingual, and nasal routes.2 The most common adverse
effect is acute withdrawal, but a lethal noncardiogenic
pulmonary edema is possible although rare (.2–3.6%).3
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